Boston Scientific acquires Penumbra

Boston Scientific Corporation has announced a definitive agreement to acquire Penumbra, a medical device firm specializing in vascular and neurovascular therapies, in a transaction valued at approximately $14.5 billion. The cash-and-stock deal positions Boston Scientific to expand its offerings in these therapeutic areas, enhancing its portfolio with Penumbra's range of mechanical thrombectomy and embolization systems.

The acquisition values Penumbra at $374 per share. Under the terms, shareholders can choose between receiving $374 in cash or 3.8721 shares of Boston Scientific stock per Penumbra share. The overall consideration will be approximately 73% cash and 27% stock, with Boston Scientific planning to finance the $11 billion cash component through existing cash reserves and new debt issuance. The transaction, subject to regulatory approvals, is expected to close in 2026.

Strategically, the acquisition will allow Boston Scientific to penetrate new segments within the vascular treatment market, including pulmonary vascular conditions such as embolism and acute limb ischemia, which are poised for growth. Mike Mahoney, Chairman and CEO of Boston Scientific, emphasized the expansion into fast-growing vascular segments as a key motivation behind the acquisition.

The deal occurs during a period of robust demand for medical technologies addressing vascular and neurovascular conditions. Penumbra has been experiencing significant financial growth, with projected revenue increases in the high teens to approximately $1.4 billion by full-year 2025. This anticipated growth trajectory enhances Boston Scientific's position in high-demand areas of patient care and therapeutic innovation.

As the acquisition awaits necessary regulatory clearances, attention will be focused on integration plans and potential synergies between the two companies. Given the financial and strategic objectives outlined by Boston Scientific, the industry will be observing how effectively the acquisition is leveraged to capture emerging opportunities within the medical device sector.